ECSP088962A - Nuevos herbicidas - Google Patents

Nuevos herbicidas

Info

Publication number
ECSP088962A
ECSP088962A EC2008008962A ECSP088962A ECSP088962A EC SP088962 A ECSP088962 A EC SP088962A EC 2008008962 A EC2008008962 A EC 2008008962A EC SP088962 A ECSP088962 A EC SP088962A EC SP088962 A ECSP088962 A EC SP088962A
Authority
EC
Ecuador
Prior art keywords
new herbicides
provides
histidine
present
lyophilized formulation
Prior art date
Application number
EC2008008962A
Other languages
English (en)
Inventor
Meera Agarkhed
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of ECSP088962A publication Critical patent/ECSP088962A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

En una modalidad, la presente invención proporciona una formulación liofilizada que comprende un anticuerpo anti-EGFR, de preferencia cetuximab; ácido lactobiónico; y una solución reguladora, de preferencia histidina. En una modalidad preferida, la presente invención proporciona una formulación liofilizada estable que comprende aproximadamente 50 mg/mL a aproximadamente 140 mg/mL de ERBITUX, aproximadamente ácido lactobiónico 0.125%, aproximadamente solución reguladora de histidina 25 mM a un pH de aproximadamente 6.0, aproximadamente Tween 80 0.005%, y aproximadamente glicina 1.875%.
EC2008008962A 2006-06-14 2008-12-11 Nuevos herbicidas ECSP088962A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81395806P 2006-06-14 2006-06-14

Publications (1)

Publication Number Publication Date
ECSP088962A true ECSP088962A (es) 2009-01-30

Family

ID=38832820

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008962A ECSP088962A (es) 2006-06-14 2008-12-11 Nuevos herbicidas

Country Status (18)

Country Link
US (1) US20100158925A1 (es)
EP (1) EP2029163A4 (es)
JP (1) JP2009540015A (es)
KR (1) KR20090021298A (es)
CN (1) CN101466404A (es)
AU (1) AU2007260769A1 (es)
BR (1) BRPI0713421A2 (es)
CA (1) CA2654794A1 (es)
CR (1) CR10493A (es)
EA (1) EA200870538A1 (es)
EC (1) ECSP088962A (es)
IL (1) IL195794A0 (es)
MA (1) MA30515B1 (es)
MX (1) MX2008015852A (es)
NO (1) NO20085131L (es)
TN (1) TNSN08511A1 (es)
WO (1) WO2007147001A2 (es)
ZA (1) ZA200810456B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002881A1 (es) * 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
CN101970493A (zh) 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
AU2010320515B2 (en) * 2009-11-20 2013-05-02 Biocon Limited Formulations of antibody
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
MX2012009755A (es) 2010-02-26 2012-09-12 Novo Nordisk As Composiciones que contienen anticuerpo estable.
BR112012022258A2 (pt) 2010-03-01 2016-10-25 Bayer Healthcare Llc anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
CA2803998A1 (en) * 2010-07-02 2012-01-05 Medimmune, Llc Antibody formulations
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
KR102034757B1 (ko) 2013-07-23 2019-10-21 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
AU2014292924B2 (en) * 2013-07-25 2019-11-21 Cytomx Therapeutics, Inc Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
CA2922562A1 (en) * 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
ES2804826T3 (es) * 2014-09-16 2021-02-09 Synermore Biologics Co Ltd Anticuerpo anti-EGFR y usos del mismo
CN105435221B (zh) * 2014-09-22 2021-09-28 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
CN106659779B (zh) * 2014-12-22 2021-05-18 西雅图免疫公司 双特异性四价抗体及其制造和使用方法
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
MA43162A (fr) 2015-11-06 2018-09-12 Acerta Pharma Bv Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
AU2017386888B2 (en) * 2016-12-28 2024-08-08 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
EP3612217A4 (en) * 2017-04-18 2020-12-30 Dr. Reddy's Laboratories Limited STABLE LIQUID PHARMACEUTICAL COMPOSITION
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3801621A1 (en) * 2018-06-01 2021-04-14 Rakuten Medical, Inc. Phthalocyanine dye conjugate compositions
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
CN114206442A (zh) 2019-01-31 2022-03-18 赛诺菲生物技术公司 用于治疗幼年特发性关节炎的抗il-6受体抗体
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
US20230220109A1 (en) * 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Compositions and methods relating to tumor activated t cell engagers
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
CN116348597A (zh) 2020-08-11 2023-06-27 佳努克斯治疗公司 可切割性接头组合物和方法
WO2022125576A1 (en) 2020-12-09 2022-06-16 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
KR20230118167A (ko) * 2020-12-11 2023-08-10 베링거 인겔하임 인터내셔날 게엠베하 다목적 적용을 위한 제형
KR20240082379A (ko) * 2021-10-03 2024-06-10 시스트이뮨, 인코포레이티드 암 치료 방법 및 이의 약제학적 조성물
WO2024058201A1 (ja) * 2022-09-16 2024-03-21 国立研究開発法人量子科学技術研究開発機構 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62158160A (ja) * 1985-12-27 1987-07-14 堺化学工業株式会社 成形触媒及び接触反応方法
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6695940B2 (en) * 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
PL1735348T3 (pl) * 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
EP1987067A4 (en) * 2006-02-15 2012-01-25 Imclone Llc ANTIBODY FORMULATION

Also Published As

Publication number Publication date
IL195794A0 (en) 2011-08-01
ZA200810456B (en) 2009-12-30
MA30515B1 (fr) 2009-06-01
JP2009540015A (ja) 2009-11-19
NO20085131L (no) 2009-03-13
CN101466404A (zh) 2009-06-24
EP2029163A2 (en) 2009-03-04
CA2654794A1 (en) 2007-12-21
KR20090021298A (ko) 2009-03-02
TNSN08511A1 (en) 2010-04-14
EP2029163A4 (en) 2010-08-11
EA200870538A1 (ru) 2009-04-28
WO2007147001A2 (en) 2007-12-21
BRPI0713421A2 (pt) 2012-03-13
WO2007147001A3 (en) 2008-07-10
US20100158925A1 (en) 2010-06-24
MX2008015852A (es) 2009-02-23
CR10493A (es) 2009-02-26
AU2007260769A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
ECSP088962A (es) Nuevos herbicidas
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
TNSN07020A1 (en) Her2 antibody composition
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
NZ719036A (en) Anti-pdl1 antibody formulations
WO2007014391A3 (en) Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
BRPI0514340A (pt) formulações de estabilização
DE602005026031D1 (de) Kristalline formen von (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
RU2009148286A (ru) Жидкая фармацевтическая композиция ботулинического токсина
CR20190400A (es) Formulaciones de anticuerpo monoclonal anti-vrs
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
PE20141151A1 (es) Proteinas de union al antigeno cd27l
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
EA201492186A1 (ru) СОДЕРЖАЩИЕ АНТИТЕЛА К Dll4 СТАБИЛИЗИРОВАННЫЕ КОМПОЗИЦИИ
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης